The last one appeared in 2005 and revealed that the expression of PDL1 in mouse cancers conferred resistance to immunotherapy by anti-CD137 activity, and blockading of PD1/PDL1 could reverse the resistance and enhance the therapeutic efficacy thereof (Hirano et al., 2005). This evidence concerns the gene TNFRSF9 and cancer.